Authorization

Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting

WOODCLIFF LAKE, N.J., March 29, 2019 /PRNewswire/ --AEisai announces today that one mini-symposium and 15 poster presentations from its oncology pipeline will be highlighted at the American Association for Cancer Research (AACR) 110th Annual Meeting in Atlanta from March 29-April 3.
Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting
"Our presence at this year's AACR conference showcases the progress we are making to better understand the mechanisms of tumorgenesis and develop precision therapeutics that address them, as well as the science underpinning the rationale for the evaluation of investigational therapies that unlock the potential of immunotherapy for more patients," said Ivan Cheung, Chairman & CEO, Eisai Inc. "We believe our relentless dedication to research and development, our robust pipeline and our key partnerships will help usher in new medicines that may fulfill the hope of improving patient care."AAA The presentations highlight Eisai's scientific expertise andAthe work underway at Eisai's drug discovery ventures across the U.S., including its oncology precision medicine-focused research and development subsidiary, H3 Biomedicine. Data to be presented include:

updated results from the lenvatinib plus pembrolizumab Phase 1b investigational trial in patients with hepatocellular carcinoma (Study 116/KEYNOTE-524), including independent imaging review (Abstract/Poster CT061/18)



pre-clinical work supporting further investigation of lenvatinib and eribulin with an anti-PD-1 antibody (Abstract/Poster 2242/1 and 4089/22)



the role of fibroblast growth factor (FGF) and the importance of FGF receptor inhibition in anti-VEGF-resistant mouse syngeneic tumor models (Abstract/Poster 196/15), in combination with anti-PD-1 antibodies in mouse RCC cells (Abstract/Poster 2242/1), and in nutrient-starved cultured human HCC cells (Abstract/Poster 190/9)



pre-clinical work on the antitumor activity seen with the investigational combination of eribulin, palbociclib and fulvestrant (Abstract/Poster 4719/9); as well as rationale for the antitumor activity of the evaluation of eribulin following palbociclib + fulvestrant for breast cancers resistant to endocrine therapy (Abstract/Poster 4759/20)



further pre-clinical investigation of eribulin and reversal of epithelial-to-mesenchymal transition (Abstract/Poster 1882/10)



the latest pre-clinical data on Eisai's structurally novel STING (stimulator of interferon genes) agonist, E7766 (Abstract 4456 and Abstract/Poster 3269/19)

"We are pleased to be able to share and discuss our multi-disciplinary collaborative research with the broader scientific community," said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer, Oncology Business Group at Eisai. "Through our precision medicine approach in the contexts of human genetics, biology and chemistry, we hope to develop tailor-designed solutions that could lead to next-generation medicines. WeAbelieve that the scientific discussions that occur at meetings like AACR are critical to informing our drug discovery and development efforts." This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.The full list of presentations at AACR 2019 with time and location is included below:

Title



Sessions



Lenvatinib



A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results



Poster Session PO.CT02Abstract/Poster No: CT061/18Monday, April 1, 20198:00am a?? 12:00pmGeorgia World Congress CenterHall B a?? Section 17M. Sung, MD



Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models



Poster Session PO.TB05.01Abstract/Poster No: 196/15Sunday, March 31, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 8K. Ichikawa



Lenvatinib induced cell death of cultured human hepatocellular carcinoma (HCC) under nutrient-starved condition through inhibition of FGFR signaling pathway



Poster Session PO.TB05.01Abstract/Poster No: 190/9Sunday, March 31, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 8T. Hoshi



Roles of FGFR Inhibition on murine RCC cells in combination antitumor activity of lenvatinib with anti-PD1 antibody via regulating IFN gamma signaling pathway



Poster Session PO.CL06.05Abstract/Poster No: 2242/1Monday, April 1, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 19Y. Adachi



Eribulin



Molecular context dictates the effects of eribulin on key EMT regulators: Snail and Slug



Poster Session PO.TB04.02Abstract/Poster No: 1882/10Monday, April 1, 20191 :00 a?? 5A:00pmGeorgia World Congress CenterHall B a?? Section 2R. Kaul



Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model



Poster Session PO.IM02.02Abstract/Poster No: 4089/22Tuesday, April 2, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 23T. Semba



Circulating levels of IFNy and neutrophil counts in breast cancer patients who received balixafortide and eribulin combination therapy



Poster Session PO.CL06.02Abstract/Poster No: 3965/21Tuesday, April 2, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 18G. Douglas



Synergistic anticancer activity of triple combinations of eribulin, palbociclib and fulvestrant in hormone dependent patient-derived xenograft (PDX) models of human breast cancer



Poster Session PO.ET06.08Abstract/Poster No: 4719/9Wednesday, April 3, 20198A:00am a?? 12:00pmGeorgia World Congress CenterHall B a?? Section 10M. Hillairet de Boisferon



Antitumor activity of eribulin after fulvestrant plus palbociclib treatments in the HR (+) human breast PDx model



Poster Session PO.ET03.06Abstract/Poster No: 4759/20Wednesday, April 3, 20198:00am a?? 12:00pmGeorgia World Congress CenterHall B a?? Section 11M. Asano



Research Pipeline



Eisai Andover innovative Medicines (AiM) Institute



Discovery of E7766: A representative of a novel class of macrocycle-bridged STING agonists (MBSAs) with pan-genotypic activity



Mini-symposium MS.CH01.01Abstract No: 4456Tuesday, April 2, 20193:00 a?? 5:00pmGeorgia World Congress CenterRoom B206D.S. Kim



Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration



Poster Session PO.IM02.11Abstract/Poster No: 3269/19Tuesday, April 2, 20198:00am a?? 12:00pmGeorgia World Congress CenterHall B a?? Section 25K.C. Huang



H3 Biomedicine



Sensitivity to splicing modulation of BCL2 family genes reveals cancer therapeutic strategies for splicing modulators



Poster Session PO.ET01.05Abstract/Poster No: 281/2Sunday, March 31, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 12P. Zhu



Integrating bulk and spatial profiling technologies for the discovery of RNA and protein biomarkers in muscle invasive bladder cancer



Poster Session PO.IM01.05Abstract/Poster No: 498/11Sunday, March 31, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 20V. Rimkunas



Heme-CMap: Generation and characterization of ~20K L1000 profiles across 11 hematologic malignant lines



Poster Session PO.BSB01.02Abstract/Poster No: 2467/7Monday, April 1, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 31C.L Huang



Eisai Oncology Business Group



Drug-Drug Interaction Potential of EZH2 Inhibitor Tazmetostat (TAZ)



Poster Session PO.CT01Abstract/Poster No: CT028/23Sunday, March 31, 20191:00 a?? 5:00pmGeorgia World Congress CenterHall B a?? Section 16J. Amengual

In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck's anti-PD-1 therapy pembrolizumab.About LENVIMAA (lenvatinib) capsules 10 mg and 4 mg
LENVIMAAA(lenvatinib) is a kinase inhibitor that is indicated:

For the treatment of patients with locally recurrent or metastatic, progressive radioactive iodine-refractory differentiated thyroid cancer (DTC)



In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy



For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)AA

LENVIMA, discovered and developed by Eisai, is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4; the platelet derived growth factor receptor alpha (PDGFRI), KIT, and RET.ALenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate 2I (FRS2I) phosphorylation. Important Safety InformationWarnings and PrecautionsHypertension.A In DTC, hypertension occurred in 73% of patients on LENVIMA (44% grade 3-4). In RCC, hypertension occurred in 42% of patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure a??160 mmHg occurred in 29% of patients, and 21% had diastolic blood pressure a??100 mmHg. In HCC, hypertension occurred in 45% of LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not reported in HCC.Serious complications of poorly controlled hypertension have been reported. Control blood pressure prior to initiation. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at reduced dose when hypertension is controlled or permanently discontinue based on severity.Cardiac Dysfunction.A Serious and fatal cardiac dysfunction can occur with LENVIMA. Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA-treated patients. Monitor for clinical symptoms or signs of cardiac dysfunction. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.Arterial Thromboembolic Events.AAAmong patients receiving LENVIMA or LENVIMA + everolimus, arterial thromboembolic events of any severity occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5 arterial thromboembolic events ranged from 2% to 3% across all clinical trials.Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.Hepatotoxicity.AAAcross clinical studies enrolling 1,327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients. Fatal events, including hepatic failure, acute hepatitis and hepatorenal syndrome, occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in 8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure occurred in 3% of LENVIMA-treated patients. 2% of patients discontinued LENVIMA due to hepatic encephalopathy and 1% discontinued due to hepatic failure.Monitor liver function prior to initiation, then every 2 weeks for the first 2 months, and at least monthly thereafter during treatment. Monitor patients with HCC closely for signs of hepatic failure, including hepatic encephalopathy. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.Renal Failure or Impairment.AASerious including fatal renal failure or impairment can occur with LENVIMA. Renal impairment was reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC, respectively. Grade 3-5 renal failure or impairment occurred in 3% of patients with DTC and 2% of patients with HCC, including 1 fatal event in each study. In RCC, renal impairment or renal failure was reported in 18% of LENVIMA + everolimusa??treated patients (10% grade 3).Initiate prompt management of diarrhea or dehydration/hypovolemia. Withhold and resume at reduced dose upon recovery or permanently discontinue for renal failure or impairment based on severity.Proteinuria.AAIn DTC and HCC, proteinuria was reported in 34% and 26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3).Monitor for proteinuria prior to initiation and periodically during treatment. If urine dipstick proteinuria a??2+ is detected, obtain a 24-hour urine protein. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.Diarrhea.AAOf the 737 LENVIMA-treated patients in DTC and HCC, diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81% of LENVIMA + everolimusa??treated patients (19% grade 3). Diarrhea was the most frequent cause of dose interruption/reduction, and diarrhea recurred despite dose reduction.Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.AFistula Formation and Gastrointestinal Perforation.AAOf the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%. Permanently discontinue in patients who develop gastrointestinal perforation of any severity or grade 3-4 fistula.QT Interval Prolongation.AAIn DTC, QT/QTc interval prolongation occurred in 9% of LENVIMA-treated patients and QT interval prolongation of >500 ms occurred in 2%. In RCC, QTc interval increases of >60 ms occurred in 11% of patients receiving LENVIMA + everolimus and QTc interval >500 ms occurred in 6%. In HCC, QTc interval increases of >60 ms occurred in 8% of LENVIMA-treated patients and QTc interval >500 ms occurred in 2%.Monitor and correct electrolyte abnormalities at baseline and periodically during treatment. Monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. Withhold and resume at reduced dose upon recovery based on severity.Hypocalcemia.A In DTC, grade 3-4 hypocalcemia occurred in 9% of LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or resolved following calcium supplementation with or without dose interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred in 6% of LENVIMA + everolimusa??treated patients. In HCC, grade 3 hypocalcemia occurred in 0.8% of LENVIMA-treated patients.Monitor blood calcium levels at least monthly and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity.Reversible Posterior Leukoencephalopathy Syndrome.AAAcross clinical studies of 1,823 patients who received LENVIMA as a single agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity and persistence of neurologic symptoms.Hemorrhagic Events.AASerious including fatal hemorrhagic events can occur with LENVIMA. In DTC, RCC, and HCC clinical trials, hemorrhagic events, of any grade, occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria. In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimusa??treated patients, including 1 fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5% of LENVIMA-treated patients, including 7 fatal hemorrhagic events.Serious tumor-related bleeds, including fatal hemorrhagic events, occurred in LENVIMA-treated patients in clinical trials and in the postmarketing setting. In postmarketing surveillance, serious and fatal carotid artery hemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than other tumors. Safety and effectiveness of LENVIMA in patients with ATC have not been demonstrated in clinical trials.Consider the risk of severe or fatal hemorrhage associated with tumor invasion or infiltration of major blood vessels (eg, carotid artery). Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction.A LENVIMA impairs exogenous thyroid suppression. In DTC, 88% of patients had baseline thyroid stimulating hormone (TSH) level a?0.5 mU/L. In patients with normal TSH at baseline, elevation of TSH level >0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of LENVIMA + everolimusa??treated patients and 21% of LENVIMA-treated patients, respectively. In patients with normal or low TSH at baseline, elevation of TSH was observed post baseline in 70% of LENVIMA-treated patients in HCC and 60% of LENVIMA + everolimusa??treated patients in RCC.Monitor thyroid function prior to initiation and at least monthly during treatment. Treat hypothyroidism according to standard medical practice.Wound Healing Complications.AAWound healing complications, including fistula formation and wound dehiscence, can occur with LENVIMA. Withhold for at least 6 days prior to scheduled surgery. Resume after surgery based on clinical judgment of adequate wound healing. Permanently discontinue in patients with wound healing complications.Embryo-fetal Toxicity.AABased on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to pregnant women. In animal reproduction studies, oral administration of lenvatinib during organogenesis at doses below the recommended clinical doses resulted in embryotoxicity, fetotoxicity, and teratogenicity in rats and rabbits. Advise pregnant women of the potential risk to a fetus; and advise females of reproductive potential to use effective contraception during treatment with LENVIMA and for at least 30 days after the last dose.Adverse Reactions
In DTC, the most common adverse reactions (a??30%) observed in LENVIMA-treated patients were hypertension (73%), fatigue (67%), diarrhea (67%), arthralgia/myalgia (62%), decreased appetite (54%), decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%), vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most common serious adverse reactions (a??2%) were pneumonia (4%), hypertension (3%), and dehydration (3%). Adverse reactions led to dose reductions in 68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most common adverse reactions (a??10%) resulting in dose reductions were hypertension (13%), proteinuria (11%), decreased appetite (10%), and diarrhea (10%); the most common adverse reactions (a??1%) resulting in discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).In RCC, the most common adverse reactions (a??30%) observed in LENVIMA + everolimusa??treated patients were diarrhea (81%), fatigue (73%), arthralgia/myalgia (55%), decreased appetite (53%), vomiting (48%), nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%), decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%). The most common serious adverse reactions (a??5%) were renal failure (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose reductions or interruption in 89% of patients. The most common adverse reactions (a??5%) resulting in dose reductions were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due to an adverse reaction occurred in 29% of patients.In HCC, the most common adverse reactions (a??20%) observed in LENVIMA-treated patients were hypertension (45%), fatigue (44%), diarrhea (39%), decreased appetite (34%), arthralgia/myalgia (31%), decreased weight (31%), abdominal pain (30%), palmar-plantar erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%), hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The most common serious adverse reactions (a??2%) were hepatic encephalopathy (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%). Adverse reactions led to dose reductions or interruption in 62% of patients. The most common adverse reactions (a??5%) resulting in dose reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%), proteinuria (7%), hypertension (6%), and palmar-plantar erythrodysesthesia syndrome (5%). Treatment discontinuation due to an adverse reaction occurred in 20% of patients. The most common adverse reactions (a??1%) resulting in discontinuation of LENVIMA were fatigue (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic failure (1%).Use in Specific Populations
Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after last dose. LENVIMA may impair fertility in males and females of reproductive potential.No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC or RCC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with RCC or DTC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end stage renal disease.No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.No dose adjustment is recommended for patients with DTC or RCC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC or RCC and severe hepatic impairment. Reduce the dose for patients with DTC or RCC and severe hepatic impairment.For more information about LENVIMA please see available fullAPrescribing Information.About HALAVENA (eribulin mesylate) Injection
HALAVENA (eribulin mesylate) Injection is a microtubule dynamics inhibitor indicated for the treatment of patients with:

Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.A



Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, HALAVEN is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells. Important Safety InformationWarnings and Precautions
Neutropenia: Severe neutropenia (ANC 1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 A? ULN and bilirubin >1.5 A? ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days. Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less. Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose. QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome. Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (a??25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%). In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (a??25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (a??5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each). Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose. Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.For more information about HALAVEN, click hereAfor the full Prescribing Information.About the Eisai and Merck Strategic Collaboration
In March 2018, Eisai and Merck, known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinibAmesylate). Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab). In addition to ongoing clinical studies evaluating the LENVIMA and KEYTRUDA combination across several different tumor types, including renal cell carcinoma, the companies will jointly initiate new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program, which will evaluate the combination to support 11 potential indications in six types of cancer (endometrial cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and urothelial cancer). The LEAP clinical program also includes a new basket trial targeting six additional cancer types (biliary tract cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma and ovarian cancer). The LENVIMA and KEYTRUDA combination is not approved in any cancer types today.About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals. For more information about Eisai, please visit www.eisai.com (for global), us.eisai.com (for U.S.) or www.eisai.co.uk (for U.K.), and connect with us on Twitter (U.S. and global) and LinkedInA(for U.S.).About H3 Biomedicine
H3 Biomedicine, Inc. is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of novel precision oncology treatments using its integrated data science, human biology and precision chemistry discovery engine with the goal of improving the lives of patients. The company was established in December 2010 as a subsidiary of Eisai's U.S. pharmaceutical operation, Eisai Inc. H3 Biomedicine focuses on sustained long-term delivery of its pipeline, collaborating with Eisai Co., Ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company. For more information, please visit www.h3biomedicine.com.
Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting
View original content to download multimedia:https://www.prnewswire.com/news-releases/eisai-announces-presentations-of-latest-research-on-oncology-pipeline-at-the-110th-american-association-for-cancer-research-aacr-annual-meeting-300820803.htmlSOURCE Eisai Inc.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«     2019    »
1234567
891011121314
15161718192021
22232425262728
293031